<DOC>
	<DOCNO>NCT01580293</DOCNO>
	<brief_summary>Haemophilia A inherited disorder one proteins , Factor VIII , need form blood clot miss present sufficient level . In person haemophilia A , clot process slow person experience bleed result serious problem potential disability . The current standard treatment severe haemophilia A regularly schedule infusion FVIII keep level high enough prevent bleeding . Due short half-life FVIII , prophylaxis may require treatment often every day . In trial safety efficacy long-acting recombinant factor VIII molecule evaluate subject severe Hemophilia A . 120-140 patient receive open label treatment long-acting rFVIII either on-demand treat bleeds prophylactically 36 week main trial plus optional extension continue treatment least 100 total exposure day ( ED ) . Patients prophylactic treatment receive study drug dose interval twice week depend observe bleeding . Patients attend treatment centre routine blood sample require keep electronic diary . Male patient age 12-65 , severe hemophilia A , previously treat FVIII least 50 exposure day may eligible study .</brief_summary>
	<brief_title>A Trial Investigating Safety Efficacy Treatment With BAY94-9027 Severe Hemophilia A</brief_title>
	<detailed_description>Subjects prophylactic treatment arm undergo clinical evaluation 10 week . Those adequate control bleed undergo randomization every 5 7 day infusion . Those continued bleed remain treatment arm increase dose . Part B-major surgery - optional sub study include collect information efficacy BAY94-9027 major surgical setting . Due rarity surgery population , enrollment sub-study may independent participation main study .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male ; 1265 year age Subjects severe hemophilia A Previously treat factor VIII minimum 150 exposure day Inhibitors FVIII ( current evidence history ) Any inherited acquire bleed disorder addition Hemophilia A Platelet count &lt; 100,000/mm3 Creatinine &gt; 2x upper limit normal AST/ALT ( aspartate aminotransferase/alanine aminotransferase ) &gt; 5x upper limit normal</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Hemophilia A , factor VIII , prophylaxis</keyword>
</DOC>